2-(N-t-butylamino)pyrazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(N-t-butylamino)pyrazine
• 英文别名: N-tert-butylpyrazin-2-amine
• 化学式: C₈H₁₃N₃
• 分子量: 151.211
• InChiKey: WSSGZRZHRHMFDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氯吡嗪 、 叔丁胺 以 乙醇 为溶剂， 反应 15.0h， 以36%的产率得到2-(N-t-butylamino)pyrazine
  参考文献：
  名称：

  N-乙基、N-异丙基和N-叔丁基取代的2-氨基吡嗪和2-氨基嘧啶的气相热解反应

  摘要：

  N-乙基(1)、N-异丙基(2)、N-叔丁基(3)取代的2-氨基吡嗪和N-乙基(4)、N-异丙基(5)和Nt-的气相消除速率丁基 (6) 取代的 2-氨基嘧啶已被测量。这些化合物经历单分子一级热解反应。在 600 K 时，吡嗪类和嘧啶类的伯、仲、叔烷基同系物的相对比率分别为 1:14.4:38.0 和 1:20.8:162.5。这些化合物的反应性已与烷氧基类似物的反应性以及彼此进行了比较。产品分析与动力学数据一起用于勾勒出研究中化合物消除反应的可行途径。© 2000 John Wiley & Sons, Inc. Int J Chem Kinet 32​​: 403–407, 2000

  DOI：

  10.1002/(sici)1097-4601(2000)32:7<403::aid-kin2>3.0.co;2-p

文献信息

• IMIDAZO[1,2-a]PYRIDINE COMPOUNDS
  申请人：SUNOVION PHARMACEUTICALS INC.

  公开号：US20130289013A1

  公开（公告）日：2013-10-31

  Imidazo[1,2-a]pyridines are disclosed. Compounds of the invention are useful therapeutic agents and their inclusion in pharmaceutical formulations and use in methods of treatment are disclosed.

  本发明公开了咪唑并[1,2-a]吡啶类化合物。本发明的化合物是有用的治疗剂，公开了它们在制药配方中的包含以及在治疗方法中的使用。
• Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
  申请人：TAIPEI MEDICAL UNIVERSITY

  公开号：US10577328B2

  公开（公告）日：2020-03-03

  The invention relates to a compound of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, multiple myeloma, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.

  本发明涉及一种式 (I) 的化合物 具有低细胞毒性，可用于阻断疾病中的泛素化-蛋白酶体系统。因此，这些化合物可用于治疗各种疾病，包括但不限于多发性骨髓瘤、癌症、神经退行性疾病、炎症性疾病、自身免疫性疾病和代谢性疾病。
• Bridged bicyclic inhibitors of menin-MLL and methods of use
  申请人：Kura Oncology, Inc.

  公开号：US10752639B2

  公开（公告）日：2020-08-25

  The present disclosure provides compounds of Formula (I-E) for inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The compounds are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin.

  本公开提供了式 (I-E) 的化合物，用于抑制 menin 与 MLL1、MLL2 和 MLL 融合肿瘤蛋白的相互作用。这些化合物可用于治疗白血病、实体癌、糖尿病和其他依赖于 MLL1、MLL2、MLL 融合蛋白和/或 menin 活性的疾病。
• Hepatitis B Antiviral Agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20160332996A1

  公开（公告）日：2016-11-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y—Z-L-R 1 (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS
  申请人：Epizyme, Inc.

  公开号：US20200039961A1

  公开（公告）日：2020-02-06

  The present disclosure relates to substituted fused bi- or tri-heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering a substituted fused bi- or tri-heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.